Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01130064 · ClinicalTrials.gov registry record · Phase 2
Efficacy of QAX576 in Asthma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 259
- Enrollment target
NCT01130064: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT01130064 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 259 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01130064, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 259 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy of 24 weeks intravenous treatment with QAX576 in patients with persistent asthma not adequately controlled with inhaled corticosteroids and long acting beta2-agonists.
Interventions
- DRUG Placebo
- BIOLOGICAL QAX576
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
What the finished NCT01130064 record still lists
NCT01130064 is an interventional study that assigns participants to a tested intervention. The registered 259 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01130064 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01130064 about?
NCT01130064 is a clinical study titled "Efficacy of QAX576 in Asthma". The purpose of this study is to investigate the efficacy of 24 weeks intravenous treatment with QAX576 in patients with persistent asthma not adequately controlled with inhaled corticosteroids and long acting beta2-agonists.
What is the current status of trial NCT01130064?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 259 participants. The study started on 2010-05. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01130064?
The interventions under investigation include: Placebo (DRUG), QAX576 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01130064?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01130064's enrollment target sits among peer trials
259 212th of 2000 higher than 1,789 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02361320 · 259 participants · NA
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
- NCT06797258 · 259 participants · NA
FlexHD® Pliable Investigation in Implant-Based Breast Reconstruction
- NCT06990425 · 259 participants · NA
CLOSM Trial: Groin Closure Using Layered Option for Suture Material
- NCT07399977 · 259 participants · NA
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia